多发性硬化共病抑郁的多基因性
研究利用加拿大、英国生物样本库和美国共106682例欧洲遗传 ancestry 个体,分析抑郁多基因评分(PGS)与多发性硬化(MS)共病抑郁的关联。Meta分析显示,MS合并抑郁者抑郁PGS高于MS不伴抑郁者(每标准差OR 1.29-1.38,p<0.05)和健康对照(每标准差OR 1.49-1.53,p<0.025),且与原发性抑郁无差异。
要点
- MS合并抑郁者抑郁PGS高于MS不伴抑郁者(每SD OR 1.29-1.38,p<0.05)。
- MS合并抑郁者抑郁PGS高于健康对照(每SD OR 1.49-1.53,p<0.025)。
- 抑郁PGS在MS共病抑郁与原发性抑郁间无差异(每SD OR 1.03-1.13,p>0.05)。
核心结论
- 在欧洲遗传 ancestry 的MS患者中,较高的抑郁遗传负荷与抑郁风险增加约30%-40%相关,且与不伴共病免疫疾病的抑郁患者相比无差异。
研究设计与样本
- 研究使用来自加拿大、英国生物样本库和美国三个来源的样本,共纳入106682例欧洲遗传 ancestry 个体。
- 个体分为MS共病抑郁组,并与MS不伴抑郁组、抑郁不伴免疫疾病组和健康人组三个对照组比较。
- 采用三种抑郁定义:终生临床诊断、自我报告的诊断和抑郁症状。
- 使用回归分析检验抑郁PGS与抑郁的关联。
主要发现
- 加拿大来源n=370(其中213例MS),英国生物样本库n=105734(其中1390例MS),美国来源n=578例MS。
- Meta分析显示,MS合并抑郁者抑郁PGS高于MS不伴抑郁者(每标准差OR范围1.29-1.38,p<0.05)。
- MS合并抑郁者抑郁PGS高于健康对照(每标准差OR范围1.49-1.53,p<0.025),无论采用何种抑郁定义及按性别分层。
- BMI PGS与抑郁症状相关(p≤0.001)。
- 抑郁PGS在MS共病抑郁与原发性抑郁之间无差异(每标准差OR范围1.03-1.13,所有p>0.05)。
局限性
- 本研究为观察性设计,作者指出该研究为进一步探索PGS用于评估MS精神障碍风险及其在非欧洲遗传 ancestry 中的应用铺平道路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Depression is common in multiple sclerosis (MS) and is associated with faster disability progression. The etiology of comorbid depression in MS remains poorly understood. Identification of individuals with a high risk of depression, through polygenic scores (PGS), may facilitate earlier identification. Previous genetic studies of depression considered depression as a primary disorder, not a comorbidity, and thus, findings may not generalize to MS. Body mass index (BMI) is a risk factor of both MS and depression, and its association may highlight differences in depression in MS. To improve the understanding of comorbid depression in MS, we will investigate PGS in people with MS, with the hypothesis that a higher depression PGS is associated with increased odds for comorbid depression in MS. METHODS: Samples from 3 sources (Canada, UK Biobank, and the United States) were used. Individuals were grouped into cases (MS/comorbid depression) and compared with 3 control groups: MS/no depression, depression/no immune disease, and healthy persons. We used 3 depression definitions: lifetime clinical diagnoses, self-reported diagnoses, and depressive symptoms. The PGS were tested in association with depression using regression. RESULTS: A total of 106,682 individuals of European genetic ancestry were used: Canada (n = 370; 213 with MS), UK Biobank (n = 105,734; 1,390 with MS), and the United States (n = 578 with MS). Meta-analyses revealed individuals with MS and depression had a higher depression PGS compared with both individuals with MS without depression (odds ratio range per SD 1.29-1.38, p < 0.05) and healthy controls (odds ratio range per SD 1.49-1.53, p < 0.025), regardless of the definition applied and when sex stratified. The BMI PGS was associated with depressive symptoms (p ≤ 0.001). The depression PGS did not differ between depression occurring as a comorbid condition with MS or as the primary condition (odds ratio range per SD 1.03-1.13, all p > 0.05). DISCUSSION: A higher depression genetic burden was associated with approximately 30%-40% increased odds of depression in European genetic ancestry participants with MS compared with those without depression and was no different compared with those with depression and no comorbid immune disease. This study paves the way for further investigations into the possible use of PGS for assessing psychiatric disorder risk in MS and its application to non-European genetic ancestries.
引用
- Kowalec K, Fitzgerald KC, Salter A, et al. Polygenicity of Comorbid Depression in Multiple Sclerosis. Neurology. 2023. PMID: 37290970. doi:10.1212/WNL.0000000000207457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。